BEVERLY HILLS, Calif., Feb. 23, 2017 (GLOBE NEWSWIRE) -- TOMI™ Environmental Solutions, Inc. ( TOMI ) (OTCQX:TOMZ), a global bacteria decontamination and infection prevention company, and its board of directors announced the formation and approval of TOMI’s scientific advisory board.
“We are honored William, Miguel and Helene – experts in intellectual property law, biosafety and infection prevention, respectively – have agreed to join our scientific advisory board,” stated Dr. Halden Shane, TOMI’s Chief Executive Officer. “We believe their support validates TOMI’s groundbreaking SteraMist™, and their guidance will help TOMI in "Innovating for a Safer World.” The team is charged with constructively challenging management to help develop strategy; ensuring the necessary resources are in place to enable us to achieve objectives in scientific research and development; and monitoring technological and regulatory trends that could impact our business as well as our performance against our goals. We believe their insight will be invaluable.”
William M. Brown, PhD, MBA, JD William M. Brown, PhD, MBA, JD is a consultant and advisor to a series of biotech and life sciences companies. Dr. Brown is a seasoned attorney in intellectual property with deep experience in healthcare-related matters. He is licensed to practice law in several states and is a registered patent attorney. His consulting experience includes intellectual property portfolio management, clinical trial contracts, and patent/business development matters. He holds a PhD from the University of Southampton, England, an MBA from Fairleigh Dickinson University, and a JD from New York Law School. Dr. Brown conducted postdoctoral research at Harvard, Johnson & Johnson, NIH, and Memorial Sloan-Kettering Cancer Center.
Miguel A. Grimaldo, MEng Miguel A. Grimaldo, MEng is an Assistant Professor for the Department of Pathology, Director of Institutional Biocontainment Resources at the University of Texas Medical Branch (UTMB) and the Director of the Biocontainment Engineering Division for the Galveston National Laboratory. His responsibilities include the review of all design, construction, commissioning and operation of High and Maximum containment laboratories as well as to ensure regulatory compliance and to conduct ongoing evaluation and recertification on all critical containment features, equipment and operations for Biosafety Level 3 (BSL‐3), Animal Biosafety Level 3 (ABSL3) and Biosafety Level 4 (BSL4) laboratory facilities at UTMB. He is also a member of the UTMB Institutional Biosafety Committee. He has served as Committee Member for development of the ANSI Z9.14‐2014 Standard ‐ Testing and Performance‐Verification Methodologies for Ventilation Systems for Biosafety Level 3 (BSL‐3) and Animal Biosafety Level 3 (ABSL‐3) facilities as well as for the 2016 Edition of the National Institute of Health (NIH) ‐ Design Requirements Manual (DRM) for Biomedical Laboratories and Animal Research Facilities. Miguel routinely serves as Biocontainment Advisor for containment laboratories nationally and internationally on design, construction and operations and also routinely contributes to a technical column in the American Biological Safety Association (ABSA) journal, Applied Biosafety entitled, “Containment Talk”. Mr. Grimaldo obtained his Masters of Engineering from the University of Louisville and Bachelor of Science degrees in Agricultural Engineering and Agricultural Economics from Texas A&M University.
Dr. Helene Paxton, MS, MT(ASCP), PhD, CIC Dr. Helene Paxton, MS, MT(ASCP), PhD, CIC, is an Infection Preventionist, owner of Bio Guidance, LLC, adjunct biology professor at Rowan University and Director of Infection Prevention at Saint Francis Healthcare. She is Infection Control Certified (CIC), board certified as an International Medical Laboratory Scientist and holds a PhD in Epidemiology. Dr. Paxton has 40 plus years’ experience in medical devices and infectious disease consulting. Dr. Paxton obtained her PhD from Kennedy Western University and her MS from Bowling Green State University.
Scientific Advisory Board Provisions and criteria have been set in the company's bylaws and scientific advisory board charter. TOMI’s scientific advisory board will always observe in the letter and spirit the duties, rights and role as a member of the company's board as stipulated in the relevant listing standards.
About TOMI™ Environmental Solutions, Inc. TOMI ™ Environmental Solutions, Inc. (OTCQX:TOMZ) is a global bacteria decontamination and infectious disease control company, providing eco-friendly environmental solutions for indoor surface disinfection through manufacturing, sales and licensing of its premier platform of Hydrogen Peroxide based product that uses Binary Ionization Technology® (BIT ™ ) , a state of the art technology for the production of its Activated Ionized Hydrogen Peroxide mist represented by the TOMI™ SteraMist™ brand.
TOMI’s products are designed to service a broad spectrum of commercial structures including hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, for non-food safety in meat and produce processing facilities, military barracks, and athletic facilities. TOMI’s products and services have also been used in single-family homes and multi-unit residences.
TOMI also develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, The Restoration Industry Association, Indoor Air Quality Association, and The International Ozone Association. For additional product information, visit www.tomimist.com or contact us at info@tomimist.com .
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Certain written and oral statements made by us may constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking statements are identified by such words and phrases as “we expect,” “expected to,” “estimates,” “estimated,” “current outlook,” “we look forward to,” “would equate to,” “projects,” “projections,” “projected to be,” “anticipates,” “anticipated,” “we believe,” “could be,” and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. They are forward-looking, and they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release.
INVESTOR RELATIONS CONTACT: Becky Herrick & Kirsten Chapman LHA Investor Relations (415) 433-3777 tomi@lhai.com MEDIA RELATIONS CONTACT: Aaron Loveland VP of Marketing and Public Affairs (240) 672-6263 aloveland@tomimist.com
